Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin.

@article{Fung2008ChronicHC,
  title={Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin.},
  author={James Yan-Yue Fung and Ching-lung Lai and Ivan F.N. Hung and John Young and Charles Cheng and Danny Wong and Man‐Fung Yuen},
  journal={The Journal of infectious diseases},
  year={2008},
  volume={198 6},
  pages={
          808-12
        }
}
BACKGROUND To date, no study has evaluated pegylated interferon for the treatment of chronic infection with hepatitis C virus (HCV) genotype 6. We aimed to determine the efficacy of pegylated interferon plus ribavirin for treating infection with genotype 6 versus genotype 1. METHODS Forty-two patients chronically infected with HCV (for genotype 1, n = 21; for genotype 6, n = 21) were treated with pegylated interferon alpha-2a (n = 20) or alpha-2b (n = 22) combined with oral ribavirin for 48… 

Figures and Tables from this paper

Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy

In conclusion, among difficult‐to‐treat genotypes, the subtype 1a is associated with a lower response to anti‐HCV therapy than subtypes 1b, 4a, and 4d.

Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country

SVR rates were high with peg-IFN and RBV therapy in Myanmar and Fibrosis scores, baseline albumin, HCV RNA levels and RVR independently predicted SVR.

Meta-Analysis: Superior Treatment Response in Asian Patients with Hepatitis C Virus Genotype 6 versus Genotype 1 with Pegylated Interferon and Ribavirin

Asian patients withHCV-6 can expect higher SVR rates than HCV-1 patients (∼63%) and EVR as a stopping rule is less clear in Asian patients with HCVs, regardless of genotype.

Randomized controlled trial of pegylated interferon‐alfa 2a and ribavirin in treatment‐naive chronic hepatitis C genotype 6

There was no significant difference in SVR rates in patients with HCV genotype 6 treated with PEG IFN‐α2a and RBV for 24 versus 48 weeks, as well as in the 24‐week and 48‐week groups.

Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis

Treatment outcomes forHCV-6 patients are superior to those for HCV-1 patients and comparable to those of HCv-2 and HCV3 patients, especially at 48 weeks, and the level of fibrosis affects treatment outcome, but SVR rates are not significantly different between genders.

Meta-analysis of patients with hepatitis C virus genotype 6: 48 weeks with pegylated interferon and ribavirin is superior to 24 weeks

The high SVR (~80 %) with 48 weeks of PEG IFN+RBV therapy may be a cost-effective option for HCV-6 patients from resource-poor regions and those who achieve RVR may receive the shorter 24-week treatment duration.

Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG‐IFN and RBV therapy

Three major HCV genotypes and eight subtypes were identified and patients with genotype 3 showed higher rate of responding to the treatment at 80.2% compared to genotypes 1 (73.5%) and 6f (65%).

Twenty‐four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a

It is indicated that 24’weeks of PEG‐IFN plus ribavirin can effectively treat patients with HCV‐6a chronic infection.

Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6.

Efforts to improve treatment outcomes with peginterferon/ribavirin should continue, as the HCV 4-6 infected population is mainly based in resource-limited settings with restricted access to the costly DAAs.
...

References

SHOWING 1-10 OF 21 REFERENCES

Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1.

Genotype 6 has a better response than genotype 1 and is associated with a higher SVR, compared with patients with seropositive anti-HCV, persistently elevated alanine transaminase levels, and detectable HCV RNA.

Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C

Early confirmation of viral reduction following initiation of antiviral therapy for chronic hepatitis C is worthwhile and provides a goal to motivate adherence during the first months of therapy and a milepost at which to reassess the need for continued treatment.

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Treatment with peginterferon-alpha2a and ribavirin may be individualized by genotype, and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribvirin was statistically inferior to low-dose Ribavirin.

Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group.

Examination of the known risk factors for acquiring HCV showed no association between genotype and mode of acquisition or histologic findings at presentation, and HCV genotypes 1a and 1b are the predominant genotypes in patients with chronic hepatitis C.

Hepatitis C Virus Genotypes in the United States: Epidemiology, Pathogenicity, and Response to Interferon Therapy

The distribution of HCV genotypes in distinct geographic regions of the United States was evaluated and the clinical characteristics of and response to interferon therapy in patients with one of several HCV Genotypes was determined.

Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C.

It is suggested that for 20 years there have been two independent ongoing hepatitis C epidemics, one affects persons who received blood transfusions or whose source of infection is unknown and infects younger persons, mainly with HCV 3a.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.

High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong

The genotype of hepatitis C virus (HCV) of 172 HCV-RNA positive serum specimens taken from patients with chronic liver diseases, thalassaemia major, chronic renal failure (CRF), haemophilia and